IP Library Granted Patent US 11,179,328
Granted Patent B2
US 11,179,328 · App. 16/747,070 · Granted Nov 23, 2021

Compositions and methods for the treatment of presbyopia

Inventor: Gerald Horn (Deerfield, IL)
Assignee: LENZ THERAPEUTICS, INC.
A61K9/0048A61K9/08A61K31/439A61K31/4409A61K45/06A61K47/02A61K47/10A61K47/26A61K47/32A61K47/34A61K47/38A61P27/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,179,328
App. No.
16/747,070
Granted
Nov 23, 2021
Kind
B2
Abstract

The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine. The compositions optionally contain a surfactant and a viscosity agent.

Claims (6)

1. A method of treating presbyopia comprising administering to a subject in need thereof an ophthalmological composition comprising aceclidine as the only active agent.

2. A method of treating presbyopia comprising administering to a subject in need thereof an ophthalmological composition comprising aceclidine as the only active agent and a viscosity agent.

3. A method of treating presbyopia comprising administering a composition comprising aceclidine as the only active agent and one or more nonionic surfactants to a subject in need thereof.

4. The method of claim 3 , wherein aceclidine is at a concentration from about 0.25% to about 2.5% w/v, wherein w/v denotes weight by total volume of the composition.

5. The method of claim 3 , wherein aceclidine is at a concentration from about 0.75% to about 2.5% w/v.

6. A method of treating low regular astigmatism, low or high irregular astigmatism, keratoconic ectasia, night vision halos/starbursts, night vision reduced contrast, and low myopia, or hyperopia, with or without astigmatism, comprising administering to a subject in need thereof an ophthalmological composition comprising aceclidine as the only active agent and a viscosity agent.

Assignments (4)
CHANGE OF NAME Recorded Apr 2, 2024
From: LENZ THERAPEUTICS, INC.
To: LENZ THERAPEUTICS OPERATIONS, INC.
Reel/Frame 066978/0082 →
MERGER AND CHANGE OF NAME Recorded Sep 29, 2021
From: PRESBYOPIA THERAPIES, INC.; PRESBYOPIA THERAPIES, INC.
To: LENZ THERAPEUTICS, INC.
Reel/Frame 057671/0014 →
CHANGE OF NAME Recorded Nov 9, 2020
From: PRESBYOPIA THERAPIES, LLC
To: PRESBYOPIA THERAPIES, INC.
Reel/Frame 054363/0516 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2020
From: HORN, GERALD; NORDAN, LEE
To: PRESBYOPIA THERAPIES, LLC
Reel/Frame 052849/0632 →
Continuity (14)
Division 16106730 · Aug 21, 2018
Continuation In Part 15956936 · Apr 19, 2018
Continuation In Part 15864703 · Jan 8, 2018
Continuation In Part 15235431 · Aug 12, 2016
Continuation In Part 15073139 · Mar 17, 2016
Continuation In Part 15073089 · Mar 17, 2016
Continuation In Part 14742903 · Jun 18, 2015
Continuation In Part 14223639 · Mar 24, 2014
Provisional Application 61938438 · Feb 11, 2014
Provisional Application 61917620 · Dec 18, 2013
Provisional Application 61904510 · Nov 15, 2013
Provisional Application 61882998 · Sep 26, 2013
Provisional Application 61871215 · Aug 28, 2013
Related Publication 20200146976A1 · May 14, 2020
Cited By (3)
US 12,414,942 US 12,533,347 US 12,653,779